Bioaffinity Technologies Inc (BIAF)

$1.25 -0.02 (-1.57%)
Market Cap 5.71M
Revenue (ttm) 9.36M
Net Income (ttm) -9.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -96.58%
Debt to Equity Ratio 0.02
Volume 78,300
Avg Vol 93,860
Day's Range N/A - N/A
Shares Out 4.50M
Stochastic %K 33%
Beta 2.45
Analysts Strong Buy
Price Target $6.00

Company Profile

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostics to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. It operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, incl...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 210 698 5334
Address:
3300 Nacogdoches Road, Suite 216, San Antonio, United States
Playdosh
Playdosh Jan. 13 at 2:15 PM
$BIAF
0 · Reply
Gavipoo69
Gavipoo69 Jan. 8 at 7:40 PM
$BIAF this really needs to hit $10. I’m like still down 10 bands right now. 😭😭💀💀
0 · Reply
MakeM0ney_444
MakeM0ney_444 Jan. 8 at 2:48 AM
$BIAF wish the market hours action had held up, this is getting frustrating
1 · Reply
Logic102
Logic102 Jan. 7 at 5:50 PM
$BIAF Yep, told you this one is way undervalued.
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 1:47 PM
$BIAF Maintains Prestigious CAP Accreditation https://www.rapidticker.com/news/biaf-bioaffinity-technologies-laboratory-maintains-prestigio
0 · Reply
Logic102
Logic102 Jan. 6 at 3:57 PM
$BIAF IMO CyPath is a $500 Million asset minimum. That's why the company is being very stubborn. They know what they have. Patience will pay here. This seems like a lottery ticket, but it's not. It's an Assymetric Risk/Reward play thanks to the CyPath backstop.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:56 AM
$BIAF RSI: 29.03, MACD: -0.1657 Vol: 0.19, MA20: 1.37, MA50: 1.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Logic102
Logic102 Jan. 2 at 9:03 PM
$BIAF With tax loss selling in the rear view mirror, the stock is ready to rock! 🎸🎤🎼
1 · Reply
Logic102
Logic102 Jan. 2 at 3:56 PM
$BIAF Having the Cologuard of Lung Cancer is a big flipping deal since this scourge kills more people annually than colon, breast and prostate cancer combined! Early detection is a game changer and CyPath has nearly identical test success as Cologuard. The sales trends are excellent and the backstop is a deal or a sale of the CyPath test if the company can't succeed on their own.
0 · Reply
trader2360
trader2360 Dec. 30 at 4:54 PM
$BIAF i am loading
1 · Reply
Latest News on BIAF
bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

Jan 7, 2026, 8:00 AM EST - 7 days ago

bioAffinity Technologies' Laboratory Maintains Prestigious College of American Pathologists (CAP) Accreditation

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

Dec 3, 2025, 8:00 AM EST - 6 weeks ago

bioAffinity Technologies' Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 8:00 AM EST - 2 months ago

bioAffinity Technologies Reports Third Quarter 2025 Financial Results

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

Nov 5, 2025, 8:00 AM EST - 2 months ago

bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test Volume

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

Oct 28, 2025, 8:00 AM EDT - 2 months ago

bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung Diseases

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

Oct 20, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

Oct 16, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Announces Notification of Allowance for U.S. Patent Application for Its Diagnostic Algorithm and Test Method for Lung Cancer

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

Oct 15, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 2:00 PM EDT - 3 months ago

WallachBeth Capital Announces The Closing of bioAffinity Technologies $1.8M Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 9, 2025, 1:00 PM EDT - 3 months ago

bioAffinity Technologies, Inc. Announces Closing of $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 4:15 PM EDT - 3 months ago

WallachBeth Capital Announces bioAffinity Technologies Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

Oct 8, 2025, 3:45 PM EDT - 3 months ago

bioAffinity Technologies, Inc. Announces Approximately $1.8 Million Registered Direct Financing of Common Stock Priced At-The-Market Under Nasdaq Rules

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

Oct 7, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Reports Record Growth in CyPath® Lung Test Volume for Third Quarter 2025

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

Sep 30, 2025, 12:44 PM EDT - 3 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

Sep 30, 2025, 12:15 PM EDT - 3 months ago

bioAffinity Technologies Announces Closing of $4.8 Million Public Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

Sep 29, 2025, 5:59 PM EDT - 3 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies Public Offering for $4.8m

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

Sep 29, 2025, 3:51 PM EDT - 3 months ago

bioAffinity Technologies Announces Pricing of $4.8 Million Public Offering

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

Sep 26, 2025, 8:00 AM EDT - 3 months ago

bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Sep 17, 2025, 8:15 AM EDT - 4 months ago

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

Sep 9, 2025, 8:00 AM EDT - 4 months ago

Case Study: CyPath® Lung Identifies Lung Cancer in Patient with Difficult-to-Diagnose Ground-Glass Pulmonary Nodules

bioAffinity Technologies Appoints New Members to Board of Directors

Aug 18, 2025, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Appoints New Members to Board of Directors

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 14, 2025, 4:15 PM EDT - 5 months ago

bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Second Quarter 2025 Results

Aug 14, 2025, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Reports Second Quarter 2025 Results

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

Aug 13, 2025, 9:25 AM EDT - 5 months ago

bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Aug 13, 2025, 8:00 AM EDT - 5 months ago

bioAffinity Technologies Reports Accelerating Growth in CyPath® Lung Test Sales

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Jul 29, 2025, 8:00 AM EDT - 6 months ago

Case Study: CyPath® Lung Detects Stage 1A Lung Cancer in High-Risk Patient With Inconclusive Imaging and Low-Risk Serum Test Results

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

Jul 22, 2025, 9:00 AM EDT - 6 months ago

Canada Awards New Patent to bioAffinity Technologies for CyPath® Lung, Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

Jul 15, 2025, 9:00 AM EDT - 6 months ago

bioAffinity Technologies Announces Notification of China Patent Award for Company's Noninvasive Lung Cancer Diagnostic

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

Jun 26, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies Scientists Present Breakthrough Cancer Research at RNA Therapeutics Conference

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

Jun 24, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

Jun 11, 2025, 9:00 AM EDT - 7 months ago

bioAffinity Technologies President and CEO Maria Zannes Appointed to American Lung Association in Texas' Leadership Board

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

May 28, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

May 20, 2025, 9:00 AM EDT - 8 months ago

bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer

bioAffinity Technologies Reports First Quarter 2025 Results

May 15, 2025, 8:30 AM EDT - 8 months ago

bioAffinity Technologies Reports First Quarter 2025 Results

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

May 8, 2025, 9:00 AM EDT - 8 months ago

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies' CyPath® Lung in Diagnosing Early-Stage Lung Cancer

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

May 7, 2025, 1:15 PM EDT - 8 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Closing of $3.25 Million Offering

May 7, 2025, 1:00 PM EDT - 8 months ago

bioAffinity Technologies Announces Closing of $3.25 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

May 6, 2025, 10:30 AM EDT - 9 months ago

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.25m Offering

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

May 6, 2025, 9:25 AM EDT - 9 months ago

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

Apr 17, 2025, 9:15 AM EDT - 9 months ago

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Mar 31, 2025, 9:28 AM EDT - 10 months ago

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Mar 26, 2025, 9:00 AM EDT - 10 months ago

Case Study: bioAffinity Technologies' CyPath® Lung Detects Second Primary Lung Cancer in Patient With History of Lung Cancer

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Mar 19, 2025, 9:00 AM EDT - 10 months ago

Case Study: bioAffinity Technologies' Positive CyPath® Lung Result Leads to Detecting Breast Cancer Recurrence

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

Mar 13, 2025, 9:00 AM EDT - 10 months ago

Physicians' Case Studies Offer Insight into Use and Benefit of CyPath® Lung in Avoiding Unnecessary Invasive Procedures and Detecting Lung Cancer

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

Mar 6, 2025, 8:00 AM EST - 11 months ago

bioAffinity Technologies Announces Targeted Actions to Cut $4 Million in Costs and Drive CyPath® Lung Sales Growth

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 12:10 PM EST - 11 months ago

WallachBeth Capital Announces Closing of bioAffinity Technologies Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

Feb 26, 2025, 11:30 AM EST - 11 months ago

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 11:05 AM EST - 11 months ago

WallachBeth Capital Announces bioAffinity Technologies Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

Feb 25, 2025, 9:58 AM EST - 11 months ago

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Jan 22, 2025, 8:00 AM EST - 1 year ago

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

Playdosh
Playdosh Jan. 13 at 2:15 PM
$BIAF
0 · Reply
Gavipoo69
Gavipoo69 Jan. 8 at 7:40 PM
$BIAF this really needs to hit $10. I’m like still down 10 bands right now. 😭😭💀💀
0 · Reply
MakeM0ney_444
MakeM0ney_444 Jan. 8 at 2:48 AM
$BIAF wish the market hours action had held up, this is getting frustrating
1 · Reply
Logic102
Logic102 Jan. 7 at 5:50 PM
$BIAF Yep, told you this one is way undervalued.
0 · Reply
JohnTrack
JohnTrack Jan. 7 at 1:47 PM
$BIAF Maintains Prestigious CAP Accreditation https://www.rapidticker.com/news/biaf-bioaffinity-technologies-laboratory-maintains-prestigio
0 · Reply
Logic102
Logic102 Jan. 6 at 3:57 PM
$BIAF IMO CyPath is a $500 Million asset minimum. That's why the company is being very stubborn. They know what they have. Patience will pay here. This seems like a lottery ticket, but it's not. It's an Assymetric Risk/Reward play thanks to the CyPath backstop.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 6 at 12:56 AM
$BIAF RSI: 29.03, MACD: -0.1657 Vol: 0.19, MA20: 1.37, MA50: 1.70 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Logic102
Logic102 Jan. 2 at 9:03 PM
$BIAF With tax loss selling in the rear view mirror, the stock is ready to rock! 🎸🎤🎼
1 · Reply
Logic102
Logic102 Jan. 2 at 3:56 PM
$BIAF Having the Cologuard of Lung Cancer is a big flipping deal since this scourge kills more people annually than colon, breast and prostate cancer combined! Early detection is a game changer and CyPath has nearly identical test success as Cologuard. The sales trends are excellent and the backstop is a deal or a sale of the CyPath test if the company can't succeed on their own.
0 · Reply
trader2360
trader2360 Dec. 30 at 4:54 PM
$BIAF i am loading
1 · Reply
TheRealRazingCane
TheRealRazingCane Dec. 30 at 2:03 AM
$BIAF
0 · Reply
Logic102
Logic102 Dec. 29 at 5:31 PM
$BIAF I was curious about the new CancerGuard screening test possibly competing with CyPath but, upon further exploration, it will very likely help products like CyPath and ColoGuard (same company as CancerGuard). Since this is a general screening test and the other two are much more specific/diagnostic. If you get a positive CancerGuard result you still don't know what cancer you might have, just that you likely have a form of cancer. Hence, if you have other signs consistent with lung cancer such as a frequent chronic cough or you are a smoker, then CyPath would be a logical follow up test.
0 · Reply
TheRealRazingCane
TheRealRazingCane Dec. 29 at 4:29 AM
$BIAF lol
0 · Reply
Stock__Hunter
Stock__Hunter Dec. 28 at 8:30 PM
$BIAF charts if set up the right way will give you a clear instant pic of potential movers and this ain't it. I we see potential dilution by charts alone. I see.. err.. charts.. lol
1 · Reply
Soly96
Soly96 Dec. 27 at 4:03 PM
$BIAF Disappointing If this goes under $1 , they might do another RS ( last one was in September)
0 · Reply
Stonecrest
Stonecrest Dec. 27 at 4:28 AM
$BIAF Just a reminder for the weak. If this stock had not done the 1-30 RS it would be under 4 cents right now.
0 · Reply
MakeM0ney_444
MakeM0ney_444 Dec. 26 at 6:15 PM
$BIAF well fuck me silly and call me Susan
1 · Reply
Alaw3s
Alaw3s Dec. 24 at 10:48 PM
$BIAF There's still no movement in these stocks. Where are the decision-makers? Why can't they find a solution to this disaster? My losses are estimated at approximately $2500.
1 · Reply
TheWolfOfCalgary
TheWolfOfCalgary Dec. 24 at 5:03 PM
$BIAF I sitting at a 2K USD loss on this shitbag, about to just sell and call it a day. Do yall think this is worth holding on to at this point ?
1 · Reply
gratitude11
gratitude11 Dec. 23 at 5:25 AM
$BIAF buy-out candidate - wouldn't be surprised to see an announcement by end of February 2026.
1 · Reply
R_NW
R_NW Dec. 22 at 2:19 PM
$BIAF They filed this after hours Friday, no PR. No quorum so they are meeting again January 19th. https://www.sec.gov/ix?doc=/Archives/edgar/data/1712762/000149315225028584/form8-k.htm
3 · Reply
R_NW
R_NW Dec. 18 at 7:52 PM
$BIAF Proxy results tomorrow. I voted no on several of the items, specifically anything that diluted the shares further. I did not feel like I should increase the employee shares from 66,000 (after dilution) to 750,000 (no one is bailing me out). I am bullish on the product, but I have also lost a lot money If they want to be compensated, then sell the company.
2 · Reply